1.95
전일 마감가:
$1.72
열려 있는:
$1.67
하루 거래량:
178.46K
Relative Volume:
0.67
시가총액:
$73.64M
수익:
-
순이익/손실:
$-8.82M
주가수익비율:
-6.50
EPS:
-0.3
순현금흐름:
$-18.01M
1주 성능:
+3.72%
1개월 성능:
-14.85%
6개월 성능:
+96.97%
1년 성능:
+62.50%
Estrella Immunopharma Inc Stock (ESLA) Company Profile
명칭
Estrella Immunopharma Inc
전화
(510) 318-9098
주소
5858 HORTON STREET, SUITE 370, EMERYVILLE
ESLA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
ESLA
Estrella Immunopharma Inc
|
1.95 | 64.96M | 0 | -8.82M | -18.01M | -0.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Estrella Immunopharma Inc 주식(ESLA)의 최신 뉴스
Estrella Immunopharma shares gain as CD19 cancer therapy progresses into phase II - MSN
Estrella Immunopharma Advances STARLIGHT-1 Trial to Phase II - TradingView
Estrella Immunopharma stock rises as cancer therapy advances to Phase II - Investing.com Canada
Estrella’s EB103 advances to Phase II after positive safety data By Investing.com - Investing.com South Africa
Estrella advances Starlight-1 trial into phase II following positive DSMB recommendation - marketscreener.com
Estrella (NASDAQ: ESLA) passes DSMB; EB103 high-dose cohort reports 100% CR - Stock Titan
Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation - Business Wire
Is Estrella Immunopharma Inc. stock a defensive play in 2025Portfolio Gains Summary & Daily Growth Stock Investment Tips - Newser
Estrella Immunopharma (NASDAQ:ESLA) Raised to “Hold” at Wall Street Zen - Defense World
How Estrella Immunopharma Inc. stock benefits from global expansionInsider Buying & Free Technical Pattern Based Buy Signals - newser.com
Published on: 2025-11-19 23:49:15 - newser.com
Is Estrella Immunopharma Inc. stock oversold or undervaluedStock Surge & Free High Accuracy Swing Entry Alerts - newser.com
What data driven models say about Estrella Immunopharma Inc.’s futureJuly 2025 Highlights & Capital Protection Trade Alerts - newser.com
Is now a turning point for Estrella Immunopharma Inc.July 2025 Chart Watch & Advanced Technical Analysis Signals - newser.com
Is Estrella Immunopharma Inc. building a consolidation baseMarket Trend Review & Precise Buy Zone Tips - newser.com
Will Estrella Immunopharma Inc. stock gain from government policies2025 Key Lessons & AI Driven Stock Price Forecasts - newser.com
Published on: 2025-11-15 19:23:21 - newser.com
Is Estrella Immunopharma Inc. reversing from oversold territoryEntry Point & Step-by-Step Swing Trade Plans - newser.com
How to integrate Estrella Immunopharma Inc. into portfolio analysis tools - newser.com
Published on: 2025-11-14 10:46:07 - newser.com
10-Q: Quarterly report - 富途牛牛
Get in on Estrella Immunopharma Inc’s (ESLA) buy-in window today! - Setenews
Estrella Immunopharma Inc (ESLA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):